Why Is CORCEPT THERAPEUTICS (CORT) Stock Down Today?

CORT stock is down 3.51% at $92.01 in morning trading as Wolfe Research downgrades the stock to Underperform with a $50 price target. The downgrade reflects concerns over valuation, which has triggered a sharp intraday selloff after a modest rebound in recent sessions. The stock opened with a -1.8% gap and has since fallen further, reaching a session low of $90.20.

What Happened

Wolfe Research issued a downgrade for Corcept Therapeutics, citing valuation concerns as the primary reason. The move comes after the company refiled its New Drug Application with the FDA for Relacorilant to treat Cushing's Syndrome, adding more data to its submission. Despite this development, the stock has struggled to hold its recent gains, with analysts focusing on the high P/E ratio of 237.2 and a market cap of $10.2 billion. The downgrade by Wolfe Research appears to have triggered immediate selling pressure, with the stock trading below its 52-week high of $97.63.

What The Data Shows

The stock opened at $93.68 and has since declined to $92.01, with volume at 0.1 million shares, which is 0.0 times the 3-month daily average. Over the last eight sessions, the stock had risen 6.5% from $89.57 to $95.36. However, the recent sell-off has erased much of that gain. Insider selling has also been notable, with 13 sales totaling $26.3 million reported in the last 90 days. The most recent insider transaction occurred on July 17, with no buys recorded in the same period.

What To Watch

The stock is currently trading near its 52-week low of $28.66. Investors should monitor the company’s regulatory progress with the FDA and any follow-up analyst coverage. No earnings date is scheduled in the near term.